Phaseline

Companies › Vincentage Pharma

Vincentage Pharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Cardiovascular, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CX11 (VCT220)–Phase 2Hypertension; Obesity & OverweightDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07349381CX11 (VCT220)Phase 1Obesity & OverweightMetabolic and endocrineJun 2026
NCT07360275CX11 (VCT220)Phase 2HypertensionCardiovascularDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Sirius Therapeutics Crystalys Therapeutics Lexicon Pharmaceuticals Rare Thyroid Therapeutics International Eddingpharm (Zhuhai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.